CSIMarket



Best Performing Stocks In Biotechnology & Pharmaceuticals Industry During This Current Quarter Q3 Of 2024



 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares are up by 5.96% on average, in Biotechnology & Pharmaceuticals Industry during this current quarter q3 of 2024.

Here are the best performing stocks in Biotechnology & Pharmaceuticals Industry.




NVAX

$15.12

$10.8600 254.93%
This Quarter Q3 of 2024


NVAX

$15.12

$10.8600 254.93%



Novavax inc

Novavax Inc stock went up 254.93% during this current quarter q3 of 2024.


Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,115.530 mill. $ 996.609 mill. $ -398.707 mill. 140 mill. - Y/Y 15.94 %
Market Cap. Revenues TTM Net Income TTM

$ 2,115.530 mill.


$ 996.609 mill.


$ -398.707 mill.

Employees Shares Outstanding P/E

370


140 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 15.94 %


MRQ Y/Y - %



DRNK

$0.0006

$0.0004 200.00%
This Quarter Q3 of 2024


DRNK

$0.0006

$0.0004 200.00%



Noho, Inc.

Noho, Inc. shares increased 200.00% during this current quarter q3 of 2024.


Noho, Inc. operates based on a business model that is not clearly known or defined, as information about their model is unavailable beyond their website.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.011 mill. $ 1.177 mill. $ -5.733 mill. 18 mill. - Y/Y 65.54 %
Market Cap. Revenues TTM Net Income TTM

$ 0.011 mill.


$ 1.177 mill.


$ -5.733 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 65.54 %


MRQ Y/Y - %



CLDI

$1.75

$1.1628 198.02%
This Quarter Q3 of 2024


CLDI

$1.75

$1.1628 198.02%



Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc stock improved 198.02% during this current quarter q3 of 2024.


Calidi Biotherapeutics Inc*s business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 62.216 mill. $ - mill. $ -34.216 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 62.216 mill.


$ - mill.


$ -34.216 mill.

Employees Shares Outstanding P/E

-


36 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HUMA

$8.4

$5.4100 180.94%
This Quarter Q3 of 2024


HUMA

$8.4

$5.4100 180.94%



Humacyte Inc

Humacyte Inc stock went up 180.94% during this current quarter q3 of 2024.


Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient*s own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 909.266 mill. $ -0.441 mill. $ -105.703 mill. 108 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 909.266 mill.


$ -0.441 mill.


$ -105.703 mill.

Employees Shares Outstanding P/E

-


108 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ADMA

$13.39

$7.3500 121.69%
This Quarter Q3 of 2024


ADMA

$13.39

$7.3500 121.69%



Adma Biologics Inc

Adma Biologics Inc shares increased 121.69% during this current quarter q3 of 2024.


Adma Biologics Inc operates as a biopharmaceutical company focused on producing and commercializing specialty plasma-derived biologics for various medical conditions. The company*s business model revolves around collecting and fractionating plasma from qualified donors to manufacture and sell therapies for immune deficiency disorders, autoimmune diseases, and other indications. Adma Biologics markets its products directly to healthcare providers, hospitals, and other healthcare institutions while prioritizing patient safety and product quality.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,165.588 mill. $ 282.136 mill. $ -3.644 mill. 236 mill. - Y/Y 42.51 %
Market Cap. Revenues TTM Net Income TTM

$ 3,165.588 mill.


$ 282.136 mill.


$ -3.644 mill.

Employees Shares Outstanding P/E

256


236 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 42.51 %


MRQ Y/Y - %



TWST

$56.15

$24.2900 76.24%
This Quarter Q3 of 2024


TWST

$56.15

$24.2900 76.24%



Twist Bioscience Corporation

Twist Bioscience Corporation shares improved 76.24% during this current quarter q3 of 2024.


Twist Bioscience Corporation operates as a biotechnology company that focuses on synthetic DNA manufacturing. Its business model consists of providing customers with custom DNA synthesis, gene libraries, and specialty components. This includes offering a variety of products and services tailored to meet the specific needs of researchers and biotech companies, enabling them to accelerate their development of personalized medicines, agricultural biotechnology, and more.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,244.291 mill. $ 277.486 mill. $ -192.138 mill. 58 mill. - Y/Y 25.13 %
Market Cap. Revenues TTM Net Income TTM

$ 3,244.291 mill.


$ 277.486 mill.


$ -192.138 mill.

Employees Shares Outstanding P/E

750


58 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 25.13 %


MRQ Y/Y - %



AGEN

$15.6

$6.6780 74.85%
This Quarter Q3 of 2024


AGEN

$15.6

$6.6780 74.85%



Agenus Inc

Agenus Inc stock improved 74.85% during this current quarter q3 of 2024.


Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 303.488 mill. $ 100.897 mill. $ -282.957 mill. 19 mill. - Y/Y 6.77 %
Market Cap. Revenues TTM Net Income TTM

$ 303.488 mill.


$ 100.897 mill.


$ -282.957 mill.

Employees Shares Outstanding P/E

-


19 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 6.77 %


MRQ Y/Y - %



PROK

$2.39

$0.9400 64.83%
This Quarter Q3 of 2024


PROK

$2.39

$0.9400 64.83%



Prokidney Corp

Prokidney Corp stock increased 64.83% during this current quarter q3 of 2024.


Prokidney Corp is a medical device company that specializes in developing innovative solutions for kidney dialysis treatment. Their business model focuses on designing, manufacturing, and marketing advanced dialysis machines and related consumables to healthcare providers worldwide. Through strategic partnerships and collaborations, Prokidney Corp aims to improve patient outcomes and enhance the overall efficiency of kidney dialysis procedures.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 147.207 mill. $ - mill. $ -221.662 mill. 62 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 147.207 mill.


$ - mill.


$ -221.662 mill.

Employees Shares Outstanding P/E

-


62 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ENZN

$0.1541

$0.0593 62.55%
This Quarter Q3 of 2024


ENZN

$0.1541

$0.0593 62.55%



Enzon Pharmaceuticals inc

Enzon Pharmaceuticals Inc stock went up 62.55% during this current quarter q3 of 2024.


Enzon Pharmaceuticals Inc. operates under a business model that focuses on the research, development, and commercialization of therapeutic drugs to address unmet medical needs. The company primarily employs a licensing strategy, partnering with other pharmaceutical companies to advance their drug candidates through clinical development and regulatory approval. By leveraging collaborations and out-licensing opportunities, Enzon aims to bring new therapies to market efficiently while maximizing shareholder value.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.437 mill. $ 2.461 mill. $ 1.496 mill. 74 mill. 23,092.55 Y/Y 44.74 %
Market Cap. Revenues TTM Net Income TTM

$ 11.437 mill.


$ 2.461 mill.


$ 1.496 mill.

Employees Shares Outstanding P/E

-


74 mill.


23,092.55

Revenue Growth Income Growth

MRQ Y/Y 44.74 %


MRQ Y/Y 62.44 %



REPL

$10.81

$3.8500 55.32%
This Quarter Q3 of 2024


REPL

$10.81

$3.8500 55.32%



Replimune Group Inc

Replimune Group Inc shares improved 55.32% during this current quarter q3 of 2024.


Replimune Group Inc has a business model centered around the development of oncolytic immunotherapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 719.979 mill. $ - mill. $ -215.794 mill. 67 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 719.979 mill.


$ - mill.


$ -215.794 mill.

Employees Shares Outstanding P/E

-


67 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MOLN

$6.21

$2.1500 52.96%
This Quarter Q3 of 2024


MOLN

$6.21

$2.1500 52.96%



Molecular Partners Ag

Molecular Partners Ag shares went up 52.96% during this current quarter q3 of 2024.


Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 203.506 mill. $ 7.038 mill. $ -61.984 mill. 33 mill. - Y/Y -96.29 %
Market Cap. Revenues TTM Net Income TTM

$ 203.506 mill.


$ 7.038 mill.


$ -61.984 mill.

Employees Shares Outstanding P/E

-


33 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -96.29 %


MRQ Y/Y - %



ELUT

$4.36

$1.5000 52.45%
This Quarter Q3 of 2024


ELUT

$4.36

$1.5000 52.45%



Elutia Inc

Elutia Inc stock went up 52.45% during this current quarter q3 of 2024.


Elutia Inc operates as a technology company that specializes in the design and manufacturing of high-performance air purification systems. Their business model focuses on developing innovative and sustainable solutions to improve indoor air quality for various industries such as healthcare, education, hospitality, and more. By incorporating advanced technology and providing reliable products, Elutia aims to create a healthier and safer environment for their customers while also driving revenue through the sale and maintenance of their air purification systems.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 104.258 mill. $ 28.194 mill. $ -47.676 mill. 24 mill. - Y/Y -55.23 %
Market Cap. Revenues TTM Net Income TTM

$ 104.258 mill.


$ 28.194 mill.


$ -47.676 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -55.23 %


MRQ Y/Y - %



ADPT

$4.03

$1.3600 50.94%
This Quarter Q3 of 2024


ADPT

$4.03

$1.3600 50.94%



Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation shares increased 50.94% during this current quarter q3 of 2024.


Adaptive Biotechnologies Corporation is a biotechnology company that utilizes its proprietary immune medicine platform to decode and analyze the human immune system. Their business model focuses on providing solutions for the diagnosis, monitoring, and treatment of various diseases such as cancer and infectious diseases. By leveraging genomics and machine learning technologies, they aim to create personalized immunotherapies and diagnostics to improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 583.161 mill. $ 179.690 mill. $ -196.006 mill. 145 mill. - Y/Y -20.72 %
Market Cap. Revenues TTM Net Income TTM

$ 583.161 mill.


$ 179.690 mill.


$ -196.006 mill.

Employees Shares Outstanding P/E

645


145 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -20.72 %


MRQ Y/Y - %



BCRX

$7.18

$2.3100 47.43%
This Quarter Q3 of 2024


BCRX

$7.18

$2.3100 47.43%



Biocryst Pharmaceuticals Inc

Biocryst Pharmaceuticals Inc shares improved 47.43% during this current quarter q3 of 2024.


Biocryst Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for rare diseases. They leverage their expertise in protein crystallography and drug design to create innovative therapies targeting specific proteins associated with certain diseases. Biocryst aims to bring these treatments to market by partnering with pharmaceutical companies or pursuing commercialization independently.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,479.540 mill. $ 355.395 mill. $ -208.585 mill. 206 mill. - Y/Y 34.87 %
Market Cap. Revenues TTM Net Income TTM

$ 1,479.540 mill.


$ 355.395 mill.


$ -208.585 mill.

Employees Shares Outstanding P/E

192


206 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 34.87 %


MRQ Y/Y - %



ALBT

$0.4681

$0.1480 46.24%
This Quarter Q3 of 2024


ALBT

$0.4681

$0.1480 46.24%



Avalon Globocare Corp

Avalon Globocare Corp stock improved 46.24% during this current quarter q3 of 2024.


Avalon Globocare Corp*s business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.053 mill. $ 1.231 mill. $ -9.230 mill. 11 mill. - Y/Y 4.38 %
Market Cap. Revenues TTM Net Income TTM

$ 5.053 mill.


$ 1.231 mill.


$ -9.230 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 4.38 %


MRQ Y/Y - %



SCLX

$1.89

$0.5500 41.04%
This Quarter Q3 of 2024


SCLX

$1.89

$0.5500 41.04%



Scilex Holding Company

Scilex Holding Company shares improved 41.04% during this current quarter q3 of 2024.


Scilex Holding Company operates as a pharmaceutical company focused on the development and commercialization of prescription drugs. Through its business model, it aims to identify and acquire assets that have the potential to address unmet medical needs and improve patient outcomes. The company primarily focuses on developing innovative, differentiated products in the therapeutic areas of pain management and neurology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 264.237 mill. $ 71.315 mill. $ -116.919 mill. 140 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 264.237 mill.


$ 71.315 mill.


$ -116.919 mill.

Employees Shares Outstanding P/E

-


140 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AVXL

$5.83

$1.5400 35.90%
This Quarter Q3 of 2024


AVXL

$5.83

$1.5400 35.90%



Anavex Life Sciences Corp

Anavex Life Sciences Corp shares improved 35.90% during this current quarter q3 of 2024.


Anavex Life Sciences Corp*s business model focuses on the development and commercialization of innovative pharmaceutical products for the treatment of central nervous system diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 480.766 mill. $ - mill. $ -40.594 mill. 82 mill. 27.76 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 480.766 mill.


$ - mill.


$ -40.594 mill.

Employees Shares Outstanding P/E

-


82 mill.


27.76

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ITOS

$16.59

$4.3500 35.54%
This Quarter Q3 of 2024


ITOS

$16.59

$4.3500 35.54%



Iteos Therapeutics Inc

Iteos Therapeutics Inc shares improved 35.54% during this current quarter q3 of 2024.


Iteos Therapeutics Inc is a company that focuses on developing innovative immunotherapies to treat cancer by targeting the tumor microenvironment.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 593.643 mill. $ - mill. $ -61.639 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 593.643 mill.


$ - mill.


$ -61.639 mill.

Employees Shares Outstanding P/E

97


36 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ATHA

$3.36

$0.8800 35.48%
This Quarter Q3 of 2024


ATHA

$3.36

$0.8800 35.48%



Athira Pharma Inc

Athira Pharma Inc stock increased 35.48% during this current quarter q3 of 2024.


Athira Pharma Inc. is a biopharmaceutical company that aims to develop novel therapies for neurodegenerative diseases. Their business model focuses on discovering and developing small molecules and antibody drugs that target certain pathological mechanisms associated with these diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 127.863 mill. $ - mill. $ -120.522 mill. 38 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 127.863 mill.


$ - mill.


$ -120.522 mill.

Employees Shares Outstanding P/E

-


38 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IKNA

$1.7

$0.4400 34.92%
This Quarter Q3 of 2024


IKNA

$1.7

$0.4400 34.92%



Ikena Oncology Inc

Ikena Oncology Inc stock improved 34.92% during this current quarter q3 of 2024.


Ikena Oncology Inc*s business model focuses on developing innovative cancer therapies through targeted drug discovery and development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 73.844 mill. $ 13.952 mill. $ -62.774 mill. 43 mill. - Y/Y -81.49 %
Market Cap. Revenues TTM Net Income TTM

$ 73.844 mill.


$ 13.952 mill.


$ -62.774 mill.

Employees Shares Outstanding P/E

-


43 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -81.49 %


MRQ Y/Y - %



PCVX

$84.17

$21.6300 34.59%
This Quarter Q3 of 2024


PCVX

$84.17

$21.6300 34.59%



Vaxcyte Inc

Vaxcyte Inc shares increased 34.59% during this current quarter q3 of 2024.


Vaxcyte Inc*s business model revolves around developing and commercializing vaccines to prevent diseases with a focus on advancing innovative approaches to address unmet medical needs. They aim to create value by leveraging their scientific expertise, conducting clinical studies, obtaining regulatory approvals, and efficiently manufacturing and distributing vaccines worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9,401.027 mill. $ - mill. $ -316.485 mill. 112 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 9,401.027 mill.


$ - mill.


$ -316.485 mill.

Employees Shares Outstanding P/E

-


112 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HALO

$52.55

$13.2700 33.78%
This Quarter Q3 of 2024


HALO

$52.55

$13.2700 33.78%



Halozyme Therapeutics Inc

Halozyme Therapeutics Inc stock went up 33.78% during this current quarter q3 of 2024.


Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6,773.012 mill. $ 862.989 mill. $ 318.802 mill. 129 mill. 21.61 Y/Y 20.81 %
Market Cap. Revenues TTM Net Income TTM

$ 6,773.012 mill.


$ 862.989 mill.


$ 318.802 mill.

Employees Shares Outstanding P/E

3,011


129 mill.


21.61

Revenue Growth Income Growth

MRQ Y/Y 20.81 %


MRQ Y/Y 93.92 %



ZURA

$3.69

$0.9100 32.73%
This Quarter Q3 of 2024


ZURA

$3.69

$0.9100 32.73%



Zura Bio Limited

Zura Bio Limited shares went up 32.73% during this current quarter q3 of 2024.


Zura Bio Limited operates on a business model focused on developing and commercializing innovative bio-based solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 173.115 mill. $ - mill. $ -17.054 mill. 47 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 173.115 mill.


$ - mill.


$ -17.054 mill.

Employees Shares Outstanding P/E

-


47 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MESO

$7.65

$1.8500 31.90%
This Quarter Q3 of 2024


MESO

$7.65

$1.8500 31.90%



Mesoblast Ltd

Mesoblast Ltd stock improved 31.90% during this current quarter q3 of 2024.


Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,653.889 mill. $ 7.501 mill. $ -81.889 mill. 739 mill. - Y/Y -26.56 %
Market Cap. Revenues TTM Net Income TTM

$ 5,653.889 mill.


$ 7.501 mill.


$ -81.889 mill.

Employees Shares Outstanding P/E

-


739 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -26.56 %


MRQ Y/Y - %



VIGL

$4.2

$1.0100 31.66%
This Quarter Q3 of 2024


VIGL

$4.2

$1.0100 31.66%



Vigil Neuroscience Inc

Vigil Neuroscience Inc shares improved 31.66% during this current quarter q3 of 2024.


Vigil Neuroscience Inc*s business model revolves around utilizing neuroscience to develop innovative solutions and technologies for various industries.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 162.998 mill. $ - mill. $ -78.920 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 162.998 mill.


$ - mill.


$ -78.920 mill.

Employees Shares Outstanding P/E

-


39 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CADL

$6.62

$1.5200 29.80%
This Quarter Q3 of 2024


CADL

$6.62

$1.5200 29.80%



Candel Therapeutics Inc

Candel Therapeutics Inc stock increased 29.80% during this current quarter q3 of 2024.


Candel Therapeutics Inc*s business model is centered around developing and commercializing advanced biotherapeutics for the treatment of cancer. They aim to leverage their proprietary oncolytic viral immunotherapy technology to deliver targeted therapies that stimulate the patient*s immune system to attack and eliminate tumors. Through partnerships and collaborations, they seek to expand their reach and accelerate the development and delivery of innovative treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 191.449 mill. $ - mill. $ -31.927 mill. 29 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 191.449 mill.


$ - mill.


$ -31.927 mill.

Employees Shares Outstanding P/E

-


29 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



KYMR

$45

$9.6700 27.37%
This Quarter Q3 of 2024


KYMR

$45

$9.6700 27.37%



Kymera Therapeutics Inc

Kymera Therapeutics Inc shares improved 27.37% during this current quarter q3 of 2024.


Kymera Therapeutics Inc is a biotechnology company that focuses on developing targeted protein degraders as potential therapeutic solutions. They utilize a proprietary technology platform to design and develop small molecules that can selectively degrade disease-causing proteins, aiming to treat various diseases including cancer and autoimmune disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,628.984 mill. $ 40.258 mill. $ -175.596 mill. 58 mill. - Y/Y -58.94 %
Market Cap. Revenues TTM Net Income TTM

$ 2,628.984 mill.


$ 40.258 mill.


$ -175.596 mill.

Employees Shares Outstanding P/E

-


58 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -58.94 %


MRQ Y/Y - %



ESLA

$1.5

$0.3200 27.12%
This Quarter Q3 of 2024


ESLA

$1.5

$0.3200 27.12%



Estrella Immunopharma Inc

Estrella Immunopharma Inc stock improved 27.12% during this current quarter q3 of 2024.


Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 52.802 mill. $ - mill. $ -4.051 mill. 35 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 52.802 mill.


$ - mill.


$ -4.051 mill.

Employees Shares Outstanding P/E

-


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DNLI

$23.33

$4.9100 26.66%
This Quarter Q3 of 2024


DNLI

$23.33

$4.9100 26.66%



Denali Therapeutics Inc

Denali Therapeutics Inc shares went up 26.66% during this current quarter q3 of 2024.


Denali Therapeutics Inc is a biotechnology company focused on developing and delivering effective therapies for neurodegenerative diseases. Their business model revolves around leveraging their deep knowledge of neurology and genetics to discover and develop innovative drugs. They aim to commercialize these therapies through strategic partnerships with pharmaceutical companies or through independent clinical development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,485.600 mill. $ - mill. $ 7.949 mill. 149 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3,485.600 mill.


$ - mill.


$ 7.949 mill.

Employees Shares Outstanding P/E

340


149 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RVMD

$46

$9.5000 26.03%
This Quarter Q3 of 2024


RVMD

$46

$9.5000 26.03%



Revolution Medicines Inc

Revolution Medicines Inc shares went up 26.03% during this current quarter q3 of 2024.


Revolution Medicines Inc operates as a biopharmaceutical company that focuses on discovering and developing new drugs to target cancers and other diseases caused by defects in cellular signaling. Their business model involves leveraging their expertise in precision oncology and molecular biology to identify novel drug candidates and advance them through preclinical and clinical development stages.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,024.722 mill. $ - mill. $ -331.337 mill. 109 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,024.722 mill.


$ - mill.


$ -331.337 mill.

Employees Shares Outstanding P/E

-


109 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AMGN

$330.15

$63.7000 23.91%
This Quarter Q3 of 2024


AMGN

$330.15

$63.7000 23.91%



Amgen Inc

Amgen Inc stock went up 23.91% during this current quarter q3 of 2024.


Amgen Inc*s business model is centered around developing, manufacturing, and commercializing innovative biotechnology products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 176,960.400 mill. $ 29,532.000 mill. $ 3,763.000 mill. 536 mill. 47.14 Y/Y 21.98 %
Market Cap. Revenues TTM Net Income TTM

$ 176,960.400 mill.


$ 29,532.000 mill.


$ 3,763.000 mill.

Employees Shares Outstanding P/E

24,200


536 mill.


47.14

Revenue Growth Income Growth

MRQ Y/Y 21.98 %


MRQ Y/Y - %



TIL

$13.51

$2.5900 23.72%
This Quarter Q3 of 2024


TIL

$13.51

$2.5900 23.72%



Instil Bio Inc

Instil Bio Inc shares increased 23.72% during this current quarter q3 of 2024.


Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 87.868 mill. $ - mill. $ -167.464 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 87.868 mill.


$ - mill.


$ -167.464 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GNFT

$4.5

$0.8317 22.67%
This Quarter Q3 of 2024


GNFT

$4.5

$0.8317 22.67%



Genfit S a

Genfit S A stock went up 22.67% during this current quarter q3 of 2024.


Genfit S has a business model centered around the research, development, and commercialization of drugs for the treatment of chronic liver diseases. They aim to create therapeutic solutions that address unmet medical needs in the field of hepatology by leveraging their expertise and innovative approaches. Their focus lies in advancing clinical programs, securing partnerships, and ultimately bringing their products to market to improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 224.178 mill. $ 42.757 mill. $ -32.361 mill. 50 mill. - Y/Y 43.70 %
Market Cap. Revenues TTM Net Income TTM

$ 224.178 mill.


$ 42.757 mill.


$ -32.361 mill.

Employees Shares Outstanding P/E

194


50 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 43.70 %


MRQ Y/Y - %



PSTX

$3.4

$0.6100 21.86%
This Quarter Q3 of 2024


PSTX

$3.4

$0.6100 21.86%



Poseida Therapeutics Inc

Poseida Therapeutics Inc shares went up 21.86% during this current quarter q3 of 2024.


Poseida Therapeutics Inc*s business model revolves around developing and commercializing gene therapies for a wide range of diseases and conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 312.454 mill. $ 52.459 mill. $ -132.011 mill. 92 mill. - Y/Y -91.96 %
Market Cap. Revenues TTM Net Income TTM

$ 312.454 mill.


$ 52.459 mill.


$ -132.011 mill.

Employees Shares Outstanding P/E

-


92 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -91.96 %


MRQ Y/Y - %



BDTX

$6.02

$1.0400 20.88%
This Quarter Q3 of 2024


BDTX

$6.02

$1.0400 20.88%



Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc stock increased 20.88% during this current quarter q3 of 2024.


Black Diamond Therapeutics Inc*s business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 311.889 mill. $ - mill. $ -79.792 mill. 52 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 311.889 mill.


$ - mill.


$ -79.792 mill.

Employees Shares Outstanding P/E

-


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ARGX

$461.94

$79.1600 20.68%
This Quarter Q3 of 2024


ARGX

$461.94

$79.1600 20.68%



Argenx se

Argenx Se stock increased 20.68% during this current quarter q3 of 2024.


Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 26,408.765 mill. $ 2,494.910 mill. $ -295.053 mill. 57 mill. - Y/Y 191.46 %
Market Cap. Revenues TTM Net Income TTM

$ 26,408.765 mill.


$ 2,494.910 mill.


$ -295.053 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 191.46 %


MRQ Y/Y - %



RLAY

$8.27

$1.3700 19.86%
This Quarter Q3 of 2024


RLAY

$8.27

$1.3700 19.86%



Relay Therapeutics Inc

Relay Therapeutics Inc stock improved 19.86% during this current quarter q3 of 2024.


Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,010.852 mill. $ 25.553 mill. $ -327.194 mill. 122 mill. - Y/Y 7,226.16 %
Market Cap. Revenues TTM Net Income TTM

$ 1,010.852 mill.


$ 25.553 mill.


$ -327.194 mill.

Employees Shares Outstanding P/E

-


122 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 7,226.16 %


MRQ Y/Y - %



KRYS

$207.88

$32.1800 18.32%
This Quarter Q3 of 2024


KRYS

$207.88

$32.1800 18.32%



Krystal Biotech Inc

Krystal Biotech Inc shares improved 18.32% during this current quarter q3 of 2024.


Krystal Biotech Inc*s business model focuses on developing and commercializing gene therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6,089.013 mill. $ 95.949 mill. $ 57.161 mill. 29 mill. 113.39 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6,089.013 mill.


$ 95.949 mill.


$ 57.161 mill.

Employees Shares Outstanding P/E

-


29 mill.


113.39

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AURA

$8.99

$1.3700 17.98%
This Quarter Q3 of 2024


AURA

$8.99

$1.3700 17.98%



Aura Biosciences Inc

Aura Biosciences Inc stock increased 17.98% during this current quarter q3 of 2024.


Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 343.285 mill. $ - mill. $ -70.836 mill. 38 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 343.285 mill.


$ - mill.


$ -70.836 mill.

Employees Shares Outstanding P/E

-


38 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DBVT

$0.8317

$0.1121 15.58%
This Quarter Q3 of 2024


DBVT

$0.8317

$0.1121 15.58%



Dbv Technologies S a

Dbv Technologies S A shares increased 15.58% during this current quarter q3 of 2024.


Dbv Technologies S.A.*s business model focuses on developing and commercializing novel therapies using its proprietary Viaskin technology platform, which aims to desensitize patients with food allergies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 79.990 mill. $ 14.941 mill. $ -79.510 mill. 96 mill. - Y/Y -35.87 %
Market Cap. Revenues TTM Net Income TTM

$ 79.990 mill.


$ 14.941 mill.


$ -79.510 mill.

Employees Shares Outstanding P/E

-


96 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -35.87 %


MRQ Y/Y - %




 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com